Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | DRS | BIO.B |
|---|---|---|
| Price | $36.60 | $365.08 |
| Change today | ▼ 0.54% | ▲ 0.00% |
| Market cap | $9.77B | $9.76B |
| Return, 3 months | -19.3% | +23.1% |
| Return, year to date | +8.0% | +17.5% |
| Return, 1 year | -18.5% | +28.2% |
| P/E (TTM) | 30.8 | 44.5 |
| P/B | 3.5 | 1.4 |
| P/E percentile vs own 5y | – | – |
| Dividend yield | 0.98% | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | – | – |
| Analyst buy share | – | – |
| RSI (14) | 37 | 97 |
| 30-day volatility | 22.4% | 0.0% |
| Max drawdown, 1 year | -28.2% | -20.4% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
